Financial management
The Blood Service is a non-profit organisation. Its operations are financed by the sale of products and services to healthcare organisations. The Blood Service is not supported by the proceeds from other Red Cross activities; instead, its costs are covered by customer fees for blood and other products and services. In addition, external funding may be sought for research or development projects, for example. Any financial surplus is not distributed but is used to ensure the continuity and development of the Blood Service’s operations.
The Blood Service’s internal result for the financial year was EUR 0.3 million. Operational activities were loss-making.
Revenue grew by 6.4% to EUR 60.8 million. In particular, sales of Stem Cell Registries, laboratory tests and plasma increased compared to the previous year. Demand for red blood cell products was lower than in the previous year, while demand for thrombocyte products increased slightly. Other operating income decreased by 7.0% compared to the previous year and amounted to EUR 1.5 million. The costs of materials, stem cell transplants and subcontracting increased by 6.8% and personnel-related expenses by 2.4%. Other costs remained unchanged. Financial income was lower than in the previous year, but in line with general developments in the financial markets.
At the end of the financial year, the Blood Service’s internal balance sheet equity totalled EUR 81.2 million. Of this, EUR 21.3 million is in the Finnish Red Cross’s equity reserve, which is intended to support research and development activities outside the Blood Service. EUR 63.6 million was invested in financial securities, and cash and bank balances amounted to EUR 7.7 million. A strong balance sheet ensures the uninterrupted continuity of the Blood Service’s critical services for months, even in the event of serious disruptions.
The Blood Service prepares an internal income statement and balance sheet for its operations. The Blood Service’s results are part of the Finnish Red Cross’s results, for which no auditor’s report has yet been issued at the time of signing the Blood Service’s balance sheet.
Turnover by product group (million euros)
The majority of the Blood Service's turnover comes from blood products.
| 2024 | 2025 | Change | Percentage of turnover | |
|---|---|---|---|---|
| Blood products | 35,3 | 36,2 | 2,5 % | 59,4 % |
| Plasma | 7,1 | 7,9 | 10,7 % | 13 % |
| Laboratory tests | 6,2 | 6,9 | 11,0 % | 11,3 % |
| Cell and tissue therapy services | 4,8 | 5,8 | 21,4 % | 9,5 % |
| Medicines | 3,3 | 3,6 | 7,2 % | 5,8 % |
| Other | 0,5 | 0,6 | 9,9 % | 0,9 % |
| Total | 57,2 | 60,8 | 6,4 % |
Cost distribution in 2025 (%)
The majority of Blood Service costs consist of personnel-related expenses.
| Personnel costs | 45 % |
| Materials and subcontracting | 23 % |
| ICT | 7 % |
| Rents (premises and equipment) | 7 % |
| Investment expenses | 5 % |
| Facility and equipment maintenance | 3 % |
| Logistics | 3 % |
| Other | 7 % |
Cost of a bag of blood in 2025 (%)
The cost of a blood product consists of several different work stages.
| Blood donation activities | 64 % |
| Laboratory activities | 16 % |
| Production | 12 % |
| Storage and transportation | 6 % |
| Medical support | 2 % |